

Supplementary Materials for  
**MicroRNA-92a–CPEB3 axis protects neurons against  
inflammatory neurodegeneration**

Iris Winkler *et al.*

Corresponding author: Manuel A. Friese, [manuel.friese@zmnh.uni-hamburg.de](mailto:manuel.friese@zmnh.uni-hamburg.de)


*Sci. Adv.* **9**, eadi6855 (2023)  
DOI: 10.1126/sciadv.adi6855

**The PDF file includes:**


Figs. S1 to S5  
Legends for tables S1 to S7

**Other Supplementary Material for this manuscript includes the following:**


Tables S1 to S7




**Fig. S1. Motor neuron-specific miRNA and mRNA purification of healthy and EAE mice.** (A) GFP-tagged AGO2 (tAGO2) visualized by GFP counterstaining in ChAT-positive cells (white arrows) of Chat-Cre-positive and Chat-Cre-negative *R26-LSL-tAGO2* mouse spinal cord. Scale bars: 25  $\mu$ m. (B) Immunohistochemical co-staining of tAGO2 and indicated cell type-specific marker proteins of the spinal cord (IBA1, microglia; CD31, endothelial cells; GFAP, astrocytes; CNPase, oligodendrocytes). Scale bars: 50  $\mu$ m. (C) qRT-PCR of cell-specific miRNAs of spinal cord lysate (input) or motor neurons purified by GFP-AGO2 immunoprecipitation (miRAP) of healthy and acute EAE (day 12 post immunization) *R26-LSL-tAGO2;Chat-Cre* mice (miR-218, motor neuronal; miR-138, neuronal; miR-9 neural; miR-150 hematopoietic). miRNA expression is relative to miR-384 (identified as endogenous control for miRNA analyses in EAE; stable expression among healthy spinal cord, EAE spinal cord, healthy motor neuron and EAE motor neuron). (D) Disease course shown as mean clinical disability score of healthy and EAE *R26-LSL-tAGO2;Chat Cre* mice of two independent cohorts that were used for miRNA profiling. Spinal cords were collected at acute EAE. (E) mRNAs were either sequenced from whole spinal cord lysate (input) or motor neurons after GFP-RPL10A immunoprecipitation (TRAP) from healthy and acute EAE (day 15 post immunization) *Chat-EGFP/Rpl10a* mice. Bar plots show normalized RNA-seq counts of cell type-specific marker genes (*Chat*, motor neurons; *Cnp*, oligodendrocytes; *Gfap*, astrocytes; *Ptprc* (CD45), immune cells). (F) Disease course shown as mean clinical disability score of healthy and EAE *Chat-EGFP/Rpl10a* mice that were used for mRNA profiling.




**Fig. S2. miR-92a and *Mir17HG* expression are not influenced by pro-inflammatory cytokines in cortical neurons.** (A) Scheme of experimental approach: primary neurons were stimulated with glutamate or pro-inflammatory cytokines for 24 hours and miRNA and gene expression tested by qRT-PCR. (B) qRT-PCR of miR-92a (relative to sno234) after stimulation of primary neurons with cytokines ( $100 \text{ ng ml}^{-1}$ ) for 24 hours. Ctrl,  $n = 8$ ; tumor necrosis factor (TNF)- $\alpha$ ,  $n = 5$ ; interferon (IFN)- $\gamma$ ,  $n = 3$ ; interleukin (IL)-1 $\beta$ ,  $n = 5$ . ROUT outlier identification; One-way ANOVA,  $F(3, 14) = 0.1282$ ,  $P = 0.9418$ . (C) qRT-PCR of *Mir17HG* (relative to *Tbp*) of neurons stimulated as in B. One-way ANOVA,  $F(3, 13) = 2.040$ ,  $P = 0.1580$ . (D) Pearson correlation of relative miR-92a and *Mir17HG* expression assessed by qRT-PCR after exposure to different pro-inflammatory cytokines for 24 hours (number of XY pairs, 10;  $P = 0.2199$ ). (E) Representative images of MAP2 immunocytochemistry of primary neurons transfected with either FAM-labeled miRNA mimics (25 nM) or transfection reagents only (control). Scale bars: 10  $\mu\text{m}$ . (F) qRT-PCR on miR-92a (relative to sno234) of miR-92a mimic or sc-miR (15 nM) transfected primary neurons ( $n = 3$ ). Student's  $t$  test,  $P = 0.0015$ . (G) Real-time viability assay of primary neurons stimulated with  $100 \text{ ng ml}^{-1}$  of the pro-inflammatory cytokines TNF- $\alpha$ , IFN- $\gamma$  or IL-1 $\beta$ . Each well was normalized to its own baseline luminescence after 5 hours, to the unstimulated vehicle control (100% cell viability) and to the max death control (2 mM glutamate, 0% cell viability);  $n = 3$ .



**Fig. S3. miR-92a regulates neuronal pathways in neuroinflammation and CPEB3 is suppressed in EAE spinal cord and MS neurons.** (A) Gene ontology and KEGG pathway over-representation analysis of identified miR-92a mRNA targets with resulting terms ordered by statistical significance (false discovery rate; FDR). (B) Immunoblotting against CPEB3 (normalized to  $\beta$ -actin) of spinal cord lysates of healthy ( $n = 4$ ) and acute EAE (day 13 post immunization) mice ( $n = 6$ ). One-tailed Mann-Whitney U test,  $P = 0.0048$ . (C) Normalized CPEB3 expression in human single nuclei data (7), control neurons  $n = 32,997$ , MS neurons  $n = 38,118$ , control non-neurons  $n = 19,212$ , MS non-neurons  $n = 56,430$ , Mann-Whitney U test against control, neurons  $P < 0.0001$ , non-neurons  $P = 0.4150$ . (D) Scheme summarizing the proposed neuronal miR-92a-Cpeb3 axis.



**Fig. S4. Characterization of  $Cpeb3^{fl/fl};Snap25-Cre$  primary neurons.** (A) qRT-PCR of  $Cpeb3$  (relative to  $Tbp$ ) in primary neurons of  $Cpeb3^{fl/fl};Snap25-Cre$  mice and  $Cpeb3^{fl/fl}$  littermate controls. Student's  $t$ -test,  $P < 0.0001$ ,  $n = 4$ . (B) Immunoblotting against CPEB3 (normalized to  $\beta$ -actin) of primary neurons derived from  $Cpeb3^{fl/fl};Snap25-Cre$  and  $Cpeb3^{fl/fl}$  mice. Student's  $t$ -test,  $P = 0.0098$ ,  $n = 4$ . Lanes were run on the same gel (noncontiguous lane indicated by black bar). (C) Scheme of experimental approach. (D) Gene ontology and KEGG pathway gene set enrichment analysis of primary neurons derived from  $Cpeb3^{fl/fl};Snap25-Cre$  versus  $Cpeb3^{fl/fl}$  control mice with resulting terms ordered by statistical significance (false discovery rate; FDR).



**Fig. S5. Characterization of *Cpeb3<sup>fl/fl</sup>;Snap25-Cre* mice.** (A) qRT-PCR of *Cpeb3* (relative to *Tbp*) in spinal cord of *Cpeb3<sup>fl/fl</sup>;Snap25-Cre* and *Cpeb3<sup>fl/fl</sup>* mice. Student's *t*-test,  $P < 0.0001$ ,  $n = 4$ . (B) Immunoblotting against CPEB3 (normalized to  $\beta$ -actin) in spinal cord of *Cpeb3<sup>fl/fl</sup>;Snap25-Cre* ( $n = 6$ ) and *Cpeb3<sup>fl/fl</sup>* mice ( $n = 7$ ). Student's *t*-test,  $P < 0.0001$ . (C) Immunohistochemical staining and quantification of  $HuD^+$  neurons in cervical spinal cord ventral horn of *Cpeb3<sup>fl/fl</sup>;Snap25-Cre* versus *Cpeb3<sup>fl/fl</sup>* control mice. Student's *t*-test,  $P = 0.6803$ ,  $n = 3$ . Scale bar: 100  $\mu m$ . (D) Staining of myelin with Luxol-Fast-Blue (LFB) in cervical spinal cords of *Cpeb3<sup>fl/fl</sup>;Snap25-Cre* versus *Cpeb3<sup>fl/fl</sup>* control mice. The LFB<sup>+</sup> area is normalized to the spinal cord area. Student's *t*-test,  $P = 0.3468$ ,  $n = 3$ . Scale bar: 250  $\mu m$ .

**Other Supplementary Material for this manuscript includes:**

**Table S1.** EAE miRNA sequencing

**Table S2.** EAE mRNA sequencing

**Table S3.** *Cpeb3*<sup>-/-</sup> neuron mRNA sequencing

**Table S4.** EAE miRNA–mRNA network

**Table S5.** qRT-PCR assays

**Table S6.** Antibodies

**Table S7.** Clinical data